[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"SunWay Biotech Co., LTD.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":86},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100590506","effect-of-exobdnf-lactic-acid-bacteria-supplement-on-cognitive-functions-sleep-and-psychological-100590506",false,"NCT06968299","Effect of ExoBDNF Lactic Acid Bacteria Supplement on Cognitive Functions, Sleep and Psychological","Effect of ExoBDNF Lactic Acid Bacteria Supplement on Cognitive Functions, Sleep and Psychological Outcomes: An Open-label Trial","Inclusion Criteria:\n\n1. Subjects must be volunteers who are 18 years of age or older, mentally clear and able to communicate.\n2. Subjects who agree to participate in this trial and voluntarily sign the trial consent form.\n\nExclusion Criteria:\n\n1. Subjects who are expected to be or have been confirmed to be pregnant (medical history).\n2. Subjects with gallbladder disease, gastrointestinal disease, gout, porphyria, or a history of gastric weight control surgery.\n3. Subjects with high blood pressure (≥160\u002F100 mmHg after resting for 10 minutes) or taking diuretics.\n4. Subjects with heart disease, hepatorenal insufficiency, hyperthyroidism or hypothyroidism, Cushing's syndrome, malignant tumors, or any other disease that may affect the results of the study.\n5. Subjects with severe hearing or visual impairment that makes it impossible to perform examinations and assessments.\n6. Subjects with any history of brain surgery, penetrating, neurovascular, infectious or other severe brain injury, epilepsy or other major neurological abnormalities, such as traumatic brain injury with loss of consciousness for more than 24 hours, or memory loss after head trauma for more than 7 days were excluded.\n7. Subjects with intellectual disabilities.\n8. Subjects who had consumed probiotics or were expected to consume probiotics within 2 weeks before the screening visit.\n9. Subjects who had participated in or were expected to participate in clinical trials within 4 weeks before the screening visit.",true,"ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","This open-label, single-group, pre\u002Fpost-test clinical study was conducted to investigate whether ExoBDNF probiotic supplementation could improve cognitive ability. It is expected that 40 subjects aged 18 years and above will be recruited, with a target of 30 cases, to take ExoBDNF probiotics for a total of 8 weeks.",[27,28,29,30],"Cognitive Functions Perceptual Disturbances","Cognitive Function Abnormal","Sleep","Psychological",[32,33,34],"Probiotics","ExoBDNF","Cognitive functions","RECRUITING","2025-11-18",{"date":38,"type":39},"2025-11-24","ACTUAL",{"date":41,"type":39},"2025-05-20",{"date":43,"type":21},"2025-12-30",{"name":45,"class":46},"SunWay Biotech Co., LTD.","INDUSTRY",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":47},"100495910","effect-of-ankascin-568-p-products-on-decreasing-hba1c-and-regulating-blood-glucose-100495910","NCT05737342","Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose","Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose- A Double-blind, Placebo-controlled Clinical Research","Inclusion Criteria:\n\n1. Men or non-pregnant women over 20 years old (women of childbearing age are not allowed to become pregnant or breastfeed during the study) adults who are sane and able to communicate.\n2. 18≦BMI≦35.\n3. Blood routine examination (CBC; Complete blood count): the mean corpuscular volume MCV should not be less than 70 fL.\n4. Blood glucose level measurement meets any of the following conditions:\n\n(1) The fasting blood sugar is between 100∼125 mg\u002FdL, and the doctor judges that there is no need to use hypoglycemic drugs for the time being.\n\n(2) Or the glycosylated hemoglobin is between 5.7∼6.4%, and the doctor judges that the use of hypoglycemic drugs is not needed for the time being.\n\n(3) Diabetic patients who have no willingness to take medicine and have not taken hypoglycemic drugs in the past month.\n\n5\\. Those without other serious diseases (cancer, heart failure, myocardial infarction, liver cirrhosis, moderate to severe liver and kidney dysfunction, stroke, etc.).\n\n6\\. Hypoglycemic drugs are not allowed to be used during the trial. If the condition changes and the use of hypoglycemic drugs is required, the trial must be withdrawn.\n\n7\\. During the test period, the daily routine and eating habits should be maintained without deliberately changing them.\n\nExclusion Criteria:\n\n1. Blood pressure: systolic blood pressure ≧ 200 mmHg or diastolic blood pressure ≧ 140 mmHg.\n2. Moderate or severe liver and kidney dysfunction (generally refers to serum aminopyruvate converting enzyme (SGPT) and serum glutamate phenylacetate transaminase (SGOT) are more than 3 times higher than the upper limit of normal value or have been diagnosed Liver cirrhosis, or glomerular filtration rate eGFR≦30 ml\u002Fmin\u002F1.73m2).\n3. Pregnant or lactating women.\n4. Diabetic patients taking hypoglycemic drugs or insulin injections.\n5. Those who take traditional Chinese medicine mainly red yeast rice.\n6. Have undergone surgery within one month.\n7. Combined with serious diseases such as heart, liver, kidney and hematopoietic system, mentally ill patients who do not meet the inclusion criteria, who do not eat the test samples according to the regulations, so that the efficacy cannot be judged or the incomplete data affect the judgment of efficacy or safety.","20 Years",{"count":57,"type":21},80,[24],"This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)",[61,62],"High Blood Sugar","Metabolic Syndrome","2025-08-21",{"date":65,"type":39},"2025-08-28",{"date":67,"type":39},"2023-04-01",{"date":69,"type":21},"2025-10-31",{"name":45,"class":46},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":59,"conditions":80,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":82,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":85,"locationsCount":47},"100495911","effect-of-ankascin-568-p-products-regulating-blood-lipid-100495911","NCT05737355","Effect of ANKASCIN 568-P Products Regulating Blood Lipid","Effect of ANKASCIN 568-P Products Regulating Blood Lipid- A Double-blind, Placebo-controlled Clinical Research","Inclusion Criteria:\n\n* Male or Female women over the age of 20 (women of childbearing age should not be pregnant or breastfeeding during the study period).\n* A sane and communicative adult.\n* 18≦BMI≦35.\n* Sub-healthy people with simple dyslipidemia and those who have been judged by the doctor that they do not need to take hypolipidemic drugs for the time being, or those who insist on not taking drugs.\n* Screening criteria Low-density lipoprotein cholesterol (LDL-C): 130\\~190 mg\u002FdL. screening criteria and high-density lipoprotein cholesterol (HLDL-C): below 50 mg\u002FdL.\n* Those without other serious diseases (cancer, heart failure, diabetes, myocardial infarction, liver cirrhosis, moderate to severe liver and kidney dysfunction, stroke, etc.).\n* During the experiment, the daily routine and eating habits should be maintained and not changed deliberately.\n\nExclusion Criteria:\n\n* Triglyceride TG≧500 mg\u002FdL.\n* Blood pressure value: systolic blood pressure ≧ 200 mmHg or diastolic blood pressure ≧ 140 mmHg.\n* Patients with moderate or severe abnormal liver and kidney function (generally referring to serum aminopyruvate converting enzyme (SGPT), serum glutamate phenylacetate transaminase (SGOT) are more than 3 times the upper limit of normal or have been diagnosed Liver cirrhosis, or glomerular filtration rate eGFR≦30 ml\u002Fmin\u002F1.73m2).\n* Pregnant or lactating women.\n* Those who take traditional Chinese medicine mainly based on red yeast rice.\n* Those who have undergone surgery within one month.\n* Those who have serious diseases such as heart, liver, kidney, and hematopoietic system, mentally ill patients who do not meet the inclusion criteria, fail to use the test product according to the regulations so that the efficacy or safety cannot be judged due to incomplete data.",{"count":57,"type":21},[24],[81],"Hyperlipidemias",{"date":65,"type":39},{"date":67,"type":39},{"date":69,"type":21},{"name":45,"class":46},""]